As Drug Industry Influence On Research Grows, So Does Potential Bias

"For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best. ... What only careful readers of the article would have gleaned is the extent of the financial connections between the drugmaker and the research."

"The trial had been funded by GlaxoSmithKline, and each of the 11 authors had received money from the company. Four were employees and held company stock. The other seven were academic experts who had received grants or consultant fees from the firm."

Peter Whoriskey reports for the Washington Post November 24, 2012.

Monday, November 26, 2012